PhRMA/RxHealth
Executive Summary
September meeting between Pharmaceutical Research & Manufacturers of America health outcomes committee and the RxHealth Value coalition was a general get acquainted session, PhRMA said. The pharmaceutical trade association has no plans to provide information to RxHealth for specific outcomes studies. RxHealth Value Executive Director John Golenski mentioned the meeting with PhRMA during a National Institute for Health Care Management conference Sept. 25 (1"The Pink Sheet" Oct. 16, p. 11)
You may also be interested in...
Interchangeability Of COX-2s And NSAIDs Will Be First RxIntelligence Study
Therapeutic interchangeability between COX-2 inhibitors and NSAIDs will be among the first research projects for RxIntelligence.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials